Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | HTR1A | P08908 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | DRD2 | P14416 | 2/20 | 0.69 |
| ▸ | HTR2C | P28335 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.63 |
| ▸ | DGKA | P23743 | 1/20 | 0.63 |
| ▸ | DGKG | P49619 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MPO | P05164 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6525350 | 1.00 | HTR2A (0.69) | HTR2ACYP3A4HPGDCYP2D6CYP1A2 | |
| SCHEMBL3429384 | 1.00 | HTR2A (0.69) | HTR2ACYP3A4HPGDCYP2D6CYP1A2 | |
| SCHEMBL22738404 | 0.90 | KDM4E (0.60) | HTR2ACYP3A4HPGDCYP2D6CYP1A2 | |
| SCHEMBL25766229 | 0.90 | HTR2A (0.68) | HTR2ACYP3A4HPGDCYP2D6CYP1A2 | |
| SCHEMBL431162 | 0.90 | HTR2A (0.68) | HTR2ACYP3A4HPGDCYP2D6CYP1A2 | |
| SCHEMBL10736627 | 0.88 | CYP2D6 (0.54) | HTR2ACYP3A4HPGDCYP2D6CYP1A2 | |
| SCHEMBL22738453 | 0.88 | HTR2A (0.54) | HTR2ACYP3A4HPGDCYP2D6CYP1A2 | |
| SCHEMBL3428187 | 0.88 | HTR2A (0.54) | HTR2ACYP3A4HPGDCYP2D6CYP1A2 | |
| Acetic Acid SCHEMBL11011364 | 0.86 | CYP3A4 (0.66) | HTR2ACYP3A4HPGDCYP2D6CYP1A2 | |
| SCHEMBL9697178 | 0.82 | HTR2A (0.56) | HTR2ACYP3A4HPGDCYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834555-B2 | Method for treating pain syndrome and other disorders | VM Therapeutics LLC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160318930-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM THERAPEUTICS LLC (US) | 2016-11-03 | — | — | US | disclosed |
| US-9402848-B2 | Method for treating pain syndrome and other disorders | VM THERAPEUTICS LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150150875-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM DISCOVERY, INC. | 2015-06-04 | — | — | US | disclosed |
| US-8980900-B2 | Method for treating pain syndrome and other disorders | VM Therapeutics, LLC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140378476-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM DISCOVERY, INC. | 2014-12-25 | — | — | US | disclosed |
| US-8865727-B2 | Method for treating pain syndrome and other disorders | VM THERAPEUTICS LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-20110053960-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM DISCOVERY INC. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378476-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | CACNA1G, CACNA1H, CACNA1A | HTR2A 606/4885CYP3A4 4426/4885HPGD 1616/4885 |
| US-20150150875-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | CACNA1G, CACNA1H, CACNA1A | HTR2A 606/4885CYP3A4 4426/4885HPGD 1616/4885 |
| US-20160318930-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | CACNA1G, CACNA1H, CACNA1A | HTR2A 606/4885CYP3A4 4426/4885HPGD 1616/4885 |
| US-20110053960-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | CACNA1G, CACNA1H, CACNA1A | HTR2A 606/4885CYP3A4 4426/4885HPGD 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.